Overview
Al Borg Diagnostics runs a large network of medical laboratories across the Middle East and Africa, offering both walk-in consumer testing (B2C) and business-to-business diagnostics for hospitals, clinics, insurers, and pharma firms. Its testing workflow uses a hub-and-spoke model with main reference labs and smaller collection sites, supported by digital pathology, an NGS lab, and a mobile app to streamline access; it provides over 1,400 tests, from routine screenings to molecular diagnostics. The company differentiates itself as the region’s largest private laboratory network with significant investments in digital pathology and molecular testing, plus strategic partnerships such as with International SOS. Its goal is to support Saudi Vision 2030 by expanding privatized, digitally connected healthcare and broad diagnostic coverage across the GCC and Africa.
Work here?Claim your company
Simplify's take
What believers are saying
- August 7, 2026 Bupa collaboration expands home-testing demand and repeat utilization.
- Q1 2026 Saudi patients rose 146%, and tests rose 163% year over year.
- Radiology and radiotherapy revenue jumped 67% in Q1 2026, broadening growth beyond pathology.
What critics are saying
- Bupa CareConnect can route insured testing away from Al Borg’s walk-in branches by 2027.
- Heavy marketing spending for Biolab KSA already squeezed Q1 2026 margins.
- Egypt and Sudan exposure leaves reported earnings vulnerable to currency shocks and shutdowns.
What makes AlBorg Diagnostics unique
- Al Borg runs Saudi Arabia’s largest private-lab network with 1,400 accredited tests.
- Its August 7, 2026 Bupa CareConnect tie-up adds home testing across Saudi Arabia.
- Digital pathology and private NGS labs support premium, harder-to-replicate diagnostics.
Help us improve and share your feedback! Did you find this helpful?